763113-22-0 | Olaparib (C₂₄H₂₃FN₄O₃)

Chemical type

• Synthetic small molecule

^[1]

• PARP inhibitor (Poly ADP-ribose polymerase inhibitor)
• Small-molecule targeted anticancer drug

^[2]

Key properties

• Inhibits poly (ADP-ribose) polymerase (PARP)
• Antitumor effects, particularly in cancers with BRCA1 or BRCA2 mutations

^[1]

• Inhibits PARP-1 and PARP-2 enzymes
• Induces synthetic lethality in cells with homologous recombination repair (HRR) deficiency
• Strong PARP-trapping activity
• Orally active targeted therapy
• Effective particularly in BRCA-mutated cancers

^[2]

• Treatment of breast cancer and ovarian cancer
• Screened in study as a potential multi-target SARS-CoV-2 antiviral

^[1]

• Treatment of metastatic castration-resistant prostate cancer (mCRPC)
• Treatment of BRCA1/2-mutated cancers
• Used as monotherapy or in combination therapy

^[2]

Classification by use

• Anti-cancer agent
• Antiviral agent (investigational)

^[1]

• Chemicals used as targeted anticancer agents
• Chemicals used as PARP inhibitors
• Chemicals used in precision oncology
• Chemicals used in DNA repair–deficient cancer therapy

^[2]

A trustworthy factory and manufacturer

1. [Cite:2] Multi-target direct-acting SARS-CoV-2 antivirals against the nucleotide-binding pockets of virus-specific proteins, Virology, Volume 577, December 2022, Pages 1-15
2. [Cite:2] PARP Inhibitor Olaparib and Its Combination Therapy in Metastatic Castration-resistant Prostate Cancer: A Systematic Review and Network Meta-analysis, European Urology Open Science, Volume 84, February 2026, Pages 1-12